| Empagliflozin group | Control group | ||||||
---|---|---|---|---|---|---|---|---|
Baseline | 1-month | 3-month | p | Baseline | 1-month | 3-month | p | |
Number | 40 | 40 | 40 | – | 30 | 30 | 30 | – |
ID R (mm) | 5.9 ± 0.9¥ | 5.8 ± 0.8 | 5.8 ± 0.8 | 0.02 | 6.0 ± 0.8 | 5.9 ± 0.8 | 6.0 ± 0.7 | NS |
IDT (mm) | 6.5 ± 0.9¥ | 6.3 ± 0.8 | 6.3 ± 0.9 | 0.02 | 6.6 ± 0.7 | 6.5 ± 0.9 | 6.6 ± 0.8 | NS |
Mean IMT (μm) | 831 ± 156^* | 793 ± 150 | 766 ± 127 | 0.0001 | 890 ± 146§ | 881 ± 160 | 841 ± 109 | 0.01 |
SPV (cm/s) | 81 ± 18 | 83.6 ± 18 | 80 ± 13 | NS | 77 ± 18 | 77 ± 17 | 80 ± 18 | NS |
EDV (cm/s) | 25 ± 6 | 25 ± 6 | 24 ± 4 | NS | 24 ± 6 | 27 ± 5 | 24 ± 8 | NS |
MV (cm/s) | 41 ± 8 | 41 ± 4 | 39 ± 6 | NS | 38 ± 7 | 41 ± 2 | 40 ± 10 | NS |